Contineum Therapeutics Inc (CTNM) Stock Price, Quote & News

Company Profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-30...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 333 5280

Website: www.contineum-tx.com

Address:

3565 General Atomics Court, Suite 200, San Diego, United States

gata2016 Feb. 12 at 3:01 PM

$CABA loved what I just heard a good data coming in! $CTNM $KYTX don't miss the boat on this.

1 · Reply

ClayClymer689 Feb. 11 at 3:35 PM

$CTNM Contineum Therapeutics; biotech focused on neuroscience and inflammation; early-stage pipeline; binary clinical catalysts ahead.

0 · Reply

kaoz Feb. 11 at 3:04 PM

$CTNM failed primary. Yikes. Someone’s pumping so big boys can dump on retail.

0 · Reply

HODLHotshot Feb. 4 at 4:05 PM

$CTNM is a technology or media company; without specifics, analysis would focus on its business model, growth trajectory, and competitive moat.

0 · Reply

BillionerOfKing Feb. 3 at 9:40 PM

$CTNM Current Stock Price: $15.24 Contracts to trade: $15.0 CTNM Feb 20 2026 Call Entry: $0.72 Exit: $1.15 ROI: 60% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

squiggleburp Jan. 16 at 2:09 PM

$CTNM Okay dokey, another 12 percent honk to the PL…. Very small position though. I never listen to myself..

0 · Reply

squiggleburp Jan. 13 at 6:07 PM

$CTNM who like squiggle dancing? I am here, have no fear…

0 · Reply

topstockalerts Jan. 13 at 5:38 PM

$CTNM Big move developing as buyers pile in 😮. Price is moving with force. This is real momentum.

0 · Reply

garygb Jan. 6 at 5:23 PM

$CTNM Buying opportunity.

0 · Reply

gata2016 Jan. 6 at 2:17 PM

$CABA For my fellow investors at $CTNM and $KYTX CABA is another in my portfolio worth a look. All three have a great deal of upside potential. Just playing the waiting game now.

0 · Reply

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 11, 2025, 10:24 PM EST - 2 months ago

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

Dec 11, 2025, 4:05 PM EST - 2 months ago

Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

Nov 24, 2025, 4:05 PM EST - 2 months ago

Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

Nov 21, 2025, 11:49 AM EST - 3 months ago

Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value

Nov 20, 2025, 4:05 PM EST - 3 months ago

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Oct 30, 2025, 4:05 PM EDT - 3 months ago

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Sep 18, 2025, 8:05 AM EDT - 5 months ago

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Aug 28, 2025, 4:05 PM EDT - 6 months ago

Contineum Therapeutics to Present at September Investor Conferences

Aug 5, 2025, 4:05 PM EDT - 6 months ago

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

Jun 25, 2025, 8:15 AM EDT - 8 months ago

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

May 15, 2025, 4:05 PM EDT - 9 months ago

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 4:05 PM EDT - 9 months ago

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Apr 28, 2025, 4:05 PM EDT - 10 months ago

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Mar 17, 2025, 4:05 PM EDT - 11 months ago

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Mar 12, 2025, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Mar 6, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Mar 4, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Mar 3, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Dec 16, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Nov 25, 2024, 8:05 AM EST - 1 year ago

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Nov 18, 2024, 8:05 AM EST - 1 year ago

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Nov 13, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics to Attend Upcoming Investor Conferences

Nov 6, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Aug 28, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Jun 24, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

RNA

Jun 13, 2024, 2:03 PM EDT - 1 year ago

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

May 20, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

May 16, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 6, 2024, 5:50 AM EDT - 2 years ago

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings

JNJ LOAR MAMO PACS RBRK ULS ZBAO

Apr 4, 2024, 9:02 PM EDT - 2 years ago

Contineum Therapeutics Announces Pricing of Initial Public Offering

gata2016 Feb. 12 at 3:01 PM

$CABA loved what I just heard a good data coming in! $CTNM $KYTX don't miss the boat on this.

1 · Reply

ClayClymer689 Feb. 11 at 3:35 PM

$CTNM Contineum Therapeutics; biotech focused on neuroscience and inflammation; early-stage pipeline; binary clinical catalysts ahead.

0 · Reply

kaoz Feb. 11 at 3:04 PM

$CTNM failed primary. Yikes. Someone’s pumping so big boys can dump on retail.

0 · Reply

HODLHotshot Feb. 4 at 4:05 PM

$CTNM is a technology or media company; without specifics, analysis would focus on its business model, growth trajectory, and competitive moat.

0 · Reply

BillionerOfKing Feb. 3 at 9:40 PM

0 · Reply

squiggleburp Jan. 16 at 2:09 PM

$CTNM Okay dokey, another 12 percent honk to the PL…. Very small position though. I never listen to myself..

0 · Reply

squiggleburp Jan. 13 at 6:07 PM

$CTNM who like squiggle dancing? I am here, have no fear…

0 · Reply

topstockalerts Jan. 13 at 5:38 PM

$CTNM Big move developing as buyers pile in 😮. Price is moving with force. This is real momentum.

0 · Reply

garygb Jan. 6 at 5:23 PM

$CTNM Buying opportunity.

0 · Reply

gata2016 Jan. 6 at 2:17 PM

$CABA For my fellow investors at $CTNM and $KYTX CABA is another in my portfolio worth a look. All three have a great deal of upside potential. Just playing the waiting game now.

0 · Reply

Arcides Jan. 5 at 6:16 PM

Bios are pupu today. $CTNM

0 · Reply

gata2016 Dec. 23 at 3:18 PM

$CTNM moved over to $KYTX just starting to run. Just moved over.

0 · Reply

SuperGreenToday Dec. 16 at 2:02 AM

$CTNM Share Price: $11.58 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $1.70 – $2.10 Target Zone: $2.76 – $3.37 Potential Upside: 53% ROI Time to Expiration: 184 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

aletz Dec. 15 at 2:24 PM

$CTNM https://www.biostockinfo.com/biotech-catalyst-ai-scanner-december-wk3/ CTNM's price action has been some what stable for several months despite a recent setback, can it change with new upcoming data?

0 · Reply

Doozio Dec. 11 at 8:30 PM

$CTNM out of the tightness it was always 🐒🍌🧠⏰♾️ all da way up da Roger or faatch 💣

0 · Reply

JarvisFlow Nov. 24 at 2:57 PM

Baird has updated their rating for Contineum Therapeutics ( $CTNM ) to Outperform with a price target of 14.

0 · Reply

rispi Nov. 21 at 4:20 PM

$CTNM no such a big red for a failure guessing why?

0 · Reply

JarvisFlow Nov. 21 at 3:00 PM

RBC Capital has adjusted their stance on Contineum Therapeutics ( $CTNM ), setting the rating to Outperform with a target price of 25 → 22.

0 · Reply

Diplo Nov. 21 at 1:46 PM

$CTNM 3k volume so far what a joke

0 · Reply

Market Cap	445.33M
Revenue (ttm)	0.00
Net Income (ttm)	-42.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	132,700
Avg Vol	261,412
Day's Range	N/A - N/A
Shares Out	29.18M
Stochastic %K	47%
Beta	1.18
Analysts	Strong Sell
Price Target	$20.33